ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling
Yogindra Vedvyas, Yanping Yang, Aroshi Mitra, Yoo-Shin Kim, Nate R. Fredette, Ricardo de Azevedo, Daniel J. Kota, Irene M. Min, Moonsoo M. Jin · 2026
Read ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling by Yogindra Vedvyas, Yanping Yang, Aroshi Mitra, Yoo-Shin Kim, Nate R. Fredette, Ricardo de Azevedo, Daniel J. Kota, Irene M. Min, Moonsoo M. Jin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13474084.txt.
Description
Yogindra Vedvyas and colleagues expand the reach of engineered T cells in 2026 by adding a second sensor to a cancer-hunting cell. Standard hunter cells target HER2, a protein rich on some tumors but sparse on others. The added sensor targets ICAM1, a sticky protein that rises on aggressive tumors. Together the pair keeps killing strong where HER2 is high and adds force where HER2 is low.
After repeated contact with tumors lacking HER2, the paired cells grew nearly tenfold and kept killing, while single-sensor cells stalled. In mice, only the paired cells fully cleared low-HER2 tumors. The design has cleared review to enter a first trial in people with stomach cancer. It offers a route to treat tumors with mixed target levels.
Catalog record
| CREATOR | Yogindra Vedvyas, Yanping Yang, Aroshi Mitra, Yoo-Shin Kim, Nate R. Fredette, Ricardo de Azevedo, Daniel J. Kota, Irene M. Min, Moonsoo M. Jin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |